Brenig Therapeutics Secures $65M in Series A Funding for Neurology Drug Development
Brenig Therapeutics is a neurology-focused drug development company utilizing an AI/ML-based discovery platform,
Company Name: Brenig Therapeutics
Location: Dover, DE
Sector: Biotechnology, Pharmaceutical
Funding Details: Raised $65 million in Series A funding led by NEA, with participation from OrbiMed, Torrey Pines Investments, and BioGeneration Ventures.
Purpose of Investment: To advance the development of BT-267, a novel therapeutic for Parkinson’s disease, through healthy volunteer studies and into proof-of-concept studies with idiopathic Parkinson’s disease patients.
Leadership: Led by CEO Iain Dukes MA DPhil, Chairman. With the financing, Ed Mathers, Partner at NEA, will join the Board of Directors.
Product and Innovation: Brenig Therapeutics is focused on the development of small molecule drugs for neurology using an AI/ML-based discovery platform in collaboration with Expert Systems Inc. Its lead candidate, BT-267, is a small molecule LRKK2 inhibitor, designed for superior brain exposure and minimal peripheral exposure to ensure efficacy and safety.
Company Growth: Brenig Therapeutics is poised to make significant advancements in neurology drug development, leveraging cutting-edge AI technologies to streamline drug discovery and development processes.
About the Company: Brenig Therapeutics aims to address complex neurological disorders by advancing scientifically sound and innovative therapeutic solutions, with a current focus on developing effective treatments for Parkinson’s disease.